ArticleHuman mutation2026
A Spatially Constrained Fibroblast-Myeloid Program Associates With Immune Exclusion and Poor Prognosis in Lung Adenocarcinoma.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although immune checkpoint blockade (ICB) therapy has improved clinical outcomes for some patients with lung adenocarcinoma (LUAD), only a subset of cases can achieve durable benefits, and primary resistance is often associated with an immune-excluded tumor microenvironment (TME). Existing studies indicate that cancer-associated fibroblasts (CAFs) are increasingly recognized as important participants in extracellular matrix (ECM) remodeling and stroma-immune crosstalk. However, in LUAD, it is still unclear which CAFs-related programs are involved in immune exclusion, particularly in relation to their spatial interactions with myeloid cell states. Methods: We integrated eight publicly available LUAD single-cell RNA-seq cohorts (164 samples; 471,501 cells) using Harmony and annotated major lineages and stromal subsets. CAFs were reclustered to resolve subtype heterogeneity, followed by pathway activity scoring, weighted gene coexpression network analysis (WGCNA), pseudotime trajectory inference (Slingshot), and regulon analysis. Bulk TCGA-LUAD data were used for immune-exclusion correlation and survival analyses. Spatial transcriptomics was applied for in situ validation, and ligand-receptor analysis together with NicheNet was used to prioritize CAFs-derived signaling interactions and downstream targets. Results: The integrated atlas identified 10 major cell lineages and revealed tumor-associated expansion of stromal and myeloid compartments. We further resolved six CAFs subtypes with distinct molecular and functional features. Tumor-enriched CAFs subsets showed stronger activation of ECM remodeling, focal adhesion, TGF- Conclusions: Multicohort single-cell integration and spatial validation define a CAFs-centered, immune-excluded niche in LUAD characterized by coordinated stromal and myeloid programs. These findings improve current understanding of CAFs heterogeneity and fibroblast-myeloid coupling in LUAD and provide a framework for future strategies aimed at targeting stromal barriers and remodeling the immune microenvironment to enhance ICB responsiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.